Pfizer Inc.
General ticker "PFE" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $141.2B (TTM average)
Pfizer Inc. follows the US Stock Market performance with the rate: 50.6%.
Estimated limits based on current volatility of 1.1%: low 26.57$, high 27.16$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-01-23, amount 0.43$ (Y6.46%)
- Total employees count: 81000 (-8.0%) as of 2024
- US accounted for 60.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Pandemic risks, Supply chain disruptions, Climate change and natural disasters, Economic downturns and volatility, Geopolitical risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.79$, 31.75$]
- 2026-12-31 to 2027-12-31 estimated range: [24.63$, 35.17$]
Financial Metrics affecting the PFE estimates:
- Positive: with PPE of 7.8 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 24.67 > 18.38
- Positive: 6.64 < Operating cash flow per share per price, % of 8.23
- Positive: 19.40 < Shareholder equity ratio, % of 41.54 <= 42.68
- Positive: Inventory ratio change, % of -12.80 <= -0.75
- Positive: Interest expense per share per price, % of 1.88 <= 3.28
- Negative: Industry operating cash flow per share per price (median), % of 6.08 <= 10.29
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.60
Short-term PFE quotes
Relationship graph
Long-term PFE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $59,553.00MM | $63,627.00MM | $62,579.00MM |
| Operating Expenses | $54,261.00MM | $47,144.00MM | $47,142.00MM |
| Operating Income | $5,292.00MM | $16,483.00MM | $15,437.00MM |
| Non-Operating Income | $-4,234.00MM | $-8,460.00MM | $-7,917.00MM |
| Interest Expense | $2,209.00MM | $3,091.00MM | $2,671.00MM |
| R&D Expense | $10,578.00MM | $10,738.00MM | $11,976.00MM |
| Income(Loss) | $1,058.00MM | $8,023.00MM | $7,520.00MM |
| Taxes | $-1,114.00MM | $-28.00MM | $-266.00MM |
| Other Income(Loss) | $-15.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $2,133.00MM | $8,020.00MM | $7,770.00MM |
| Stockholders Equity | $89,014.00MM | $88,203.00MM | $86,476.00MM |
| Inventory | $10,189.00MM | $10,851.00MM | $10,654.00MM |
| Assets | $226,501.00MM | $213,396.00MM | $208,160.00MM |
| Operating Cash Flow | $8,700.00MM | $12,744.00MM | $11,705.00MM |
| Capital expenditure | $3,907.00MM | $2,909.00MM | $2,629.00MM |
| Investing Cash Flow | $-32,278.00MM | $2,652.00MM | $-1,351.00MM |
| Financing Cash Flow | $26,066.00MM | $-17,140.00MM | $-10,304.00MM |
| Earnings Per Share** | $0.38 | $1.42 | $1.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.